Trials / Terminated
TerminatedNCT01113801
A Study in Participants With Diabetic Kidney Disease
A Randomized, Double-Masked, Placebo-Controlled, Multicenter, Phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients With Diabetic Kidney Disease Due to Type 1 or Type 2 Diabetes
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 417 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 25 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine if LY2382770 is safe and effective at protecting kidney function in participants with kidney disease due to diabetes.
Detailed description
The primary objective is to determine if LY2382770, administered monthly for 1 year, is more effective than placebo at slowing the progression of diabetic kidney disease in participants treated with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY2382770 | Subcutaneous injection given monthly for 12 months |
| DRUG | Placebo | Subcutaneous injection given monthly for 12 months |
Timeline
- Start date
- 2010-07-01
- Primary completion
- 2014-05-01
- Completion
- 2014-07-01
- First posted
- 2010-04-30
- Last updated
- 2019-09-17
- Results posted
- 2017-12-13
Locations
78 sites across 7 countries: United States, Australia, Czechia, France, Hungary, Israel, Puerto Rico
Source: ClinicalTrials.gov record NCT01113801. Inclusion in this directory is not an endorsement.